Last updated: 20 June 2024 at 5:00pm EST

Robert Lorne Hopfner Net Worth




The estimated Net Worth of Robert Lorne Hopfner is at least $30.2 Million dollars as of 1 August 2023. Robert Hopfner owns over 833,333 units of Inozyme Pharma stock worth over $8,188,771 and over the last 4 years Robert sold INZY stock worth over $22,040,645.

Robert Hopfner INZY stock SEC Form 4 insiders trading

Robert has made over 15 trades of the Inozyme Pharma stock since 2020, according to the Form 4 filled with the SEC. Most recently Robert bought 833,333 units of INZY stock worth $3,999,998 on 1 August 2023.

The largest trade Robert's ever made was buying 1,070,000 units of Inozyme Pharma stock on 19 April 2022 worth over $3,948,300. On average, Robert trades about 181,898 units every 52 days since 2020. As of 1 August 2023 Robert still owns at least 1,571,741 units of Inozyme Pharma stock.

You can see the complete history of Robert Hopfner stock trades at the bottom of the page.



What's Robert Hopfner's mailing address?

Robert's mailing address filed with the SEC is C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON, MA, 02210.

Insiders trading at Inozyme Pharma

Over the last 4 years, insiders at Inozyme Pharma have traded over $0 worth of Inozyme Pharma stock and bought 11,149,230 units worth $104,131,475 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of $2,019,505. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth $130,250.



What does Inozyme Pharma do?

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.



What does Inozyme Pharma's logo look like?

Inozyme Pharma, Inc. logo

Complete history of Robert Hopfner stock trades at Vaxcyte and Inozyme Pharma

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
1 Aug 2023 Robert Lorne Hopfner
Buy 833,333 $4.80 $3,999,998
1 Aug 2023
1,571,741
11 May 2023 Robert Lorne Hopfner
Buy 447,932 $6.36 $2,848,848
11 May 2023
3,661,518
29 Mar 2023 Robert Lorne Hopfner
Buy 344,592 $4.54 $1,564,448
29 Mar 2023
3,213,586
27 Mar 2023 Robert Lorne Hopfner
Buy 207,840 $4.05 $841,752
27 Mar 2023
2,868,994
19 Apr 2022 Robert Lorne Hopfner
Buy 1,070,000 $3.69 $3,948,300
19 Apr 2022
2,661,154
28 Jul 2020 Robert Lorne Hopfner
Buy 187,500 $16.00 $3,000,000
28 Jul 2020
1,591,154
8 Feb 2021 Robert Lorne Hopfner
Director
Sale 378,698 $27.34 $10,353,603
8 Feb 2021
1,405,418
2 Feb 2021 Robert Lorne Hopfner
Director
Sale 17,002 $25.12 $427,090
2 Feb 2021
1,784,116
28 Jan 2021 Robert Lorne Hopfner
Director
Sale 2,000 $25.07 $50,140
28 Jan 2021
1,801,118
25 Jan 2021 Robert Lorne Hopfner
Director
Sale 55,254 $25.62 $1,415,607
25 Jan 2021
1,803,118
20 Jan 2021 Robert Lorne Hopfner
Director
Sale 30,529 $25.28 $771,773
20 Jan 2021
1,858,372
14 Jan 2021 Robert Lorne Hopfner
Director
Sale 91,111 $25.71 $2,342,464
14 Jan 2021
1,888,901
11 Jan 2021 Robert Lorne Hopfner
Director
Sale 97,343 $26.29 $2,559,147
11 Jan 2021
1,980,012
6 Jan 2021 Robert Lorne Hopfner
Director
Sale 145,612 $28.30 $4,120,820
6 Jan 2021
2,077,355
16 Jun 2020 Robert Lorne Hopfner
Director
Buy 93,000 $16.00 $1,488,000
16 Jun 2020
2,222,967


Inozyme Pharma executives and stock owners

Inozyme Pharma executives and other stock owners filed with the SEC include: